Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Cash from Operations (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Cash from Operations for 4 consecutive years, with 26722000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 45.96% to 26722000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 93090000.0 through Dec 2025, down 14.61% year-over-year, with the annual reading at 93090000.0 for FY2025, 14.61% down from the prior year.
  • Cash from Operations hit 26722000.0 in Q4 2025 for Taysha Gene Therapies, down from 24166000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 14712000.0 in Q4 2022 to a low of 40939000.0 in Q1 2022.
  • Historically, Cash from Operations has averaged 20982687.5 across 4 years, with a median of 20844500.0 in 2023.
  • Biggest YoY gain for Cash from Operations was 50.69% in 2023; the steepest drop was 209.55% in 2023.
  • Year by year, Cash from Operations stood at 14712000.0 in 2022, then crashed by 209.55% to 16117000.0 in 2023, then fell by 13.59% to 18308000.0 in 2024, then crashed by 45.96% to 26722000.0 in 2025.
  • Business Quant data shows Cash from Operations for TSHA at 26722000.0 in Q4 2025, 24166000.0 in Q3 2025, and 20182000.0 in Q2 2025.